Canakinumab: a promising monoclonal antibody in the treatment of cardiovascular diseases
Canakinumab is a totally human monoclonal antibody anti-IL-1β developed by
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Canakinumab is a totally human monoclonal antibody anti-IL-1β developed by
association with conditions such as metabolic disorders, gastrointestinal diseases, and mental health disorders. Despite promising therapeutic applications, including probiotics and fecal microbiota transplantation…
that although immunotherapy is not a universal cure, it represents one of the most promising advances in modern oncology
from different disciplines [5]. Conclusion Pharmaceutical lead optimization is a vital step in transforming promising lead compounds into viable drug candidates. By systematically improving efficacy, selectivity…
Chepa, a widely consumed processed fish product in Bangladesh, is prepared through
including gastrointestinal, respiratory, chronic diseases, musculoskeletal pain, and supportive cancer care. It also shows promise for anxiety, depression, Attention-Deficit/Hyperactivity Disorder, and in veterinary…
Irene P. Vasquez* PDF Share this article
Green hydrogen is critical for sustainable energy systems and industrial decarbonization. Research
foundations, architectures, and diverse applications. QNNs harness quantum mechanics for enhanced computational power, showing promise in image processing, finance, and medical analysis. Key topics include variational…
Mahmoud Farouk* HTML PDF Share this article
Amina Idris* HTML PDF Share this article
Viktor S. Ivanov* PDF Share this article
For authors and organisers
Find the right journal for your paper and submit your manuscript.